As of November 6, 2026, BridgeBio Oncology Therapeutics, Inc. is a publicly traded company (Nasdaq: BBOT). The largest holder reporting an active stake on Schedule 13D is Helix Holdings II LLC, at 22.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Bihua Chen, a director and 10% owner (22.32%) (Schedule 13D/A, August 13, 2025).
On the record Leadership changes at BridgeBio Oncology Therapeutics, Inc. (2026)
Is this your company?
About to sign with, pay or invest in BridgeBio Oncology Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is BridgeBio Oncology Therapeutics, Inc. a real, registered company?
- BridgeBio Oncology Therapeutics, Inc. files with the SEC under CIK 1869105 (its SEC filings).
- Its shares are listed under the ticker BBOT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BridgeBio Oncology Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Michelle Doig, Director (Form 8-K filed 2026-06-22). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bihua Chen (filed 2026-07-06).
Who are BridgeBio Oncology Therapeutics, Inc.'s owners and officers?
BridgeBio Oncology Therapeutics, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-07-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-07-06 | Bihua Chen | 22.32% |
| Schedule 13G/A, 2025-11-14 | Citadel Advisors LLC | 3.2% |
| Schedule 13G/A, 2025-11-13 | Adage Capital Management, L.P. | 1.88% |
| Schedule 13G, 2025-09-03 | Bc Global Opportunities Ix LP | 5.5% |
| Schedule 13D, 2025-08-18 | Bridgebio Pharma LLC | 17.5% |
| Schedule 13G, 2025-08-18 | Deerfield Management Company, L.P. | 6.17% |
| Schedule 13D/A, 2025-08-13 | Helix Holdings Ii LLC | 22.6% |
| Schedule 13G/A, 2025-07-30 | Millennium Management LLC | 4.7% |
| Schedule 13G, 2025-07-24 | Sculptor Capital LP | 5.12% |
Questions about who owns BridgeBio Oncology Therapeutics, Inc.
Who owns BridgeBio Oncology Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of BridgeBio Oncology Therapeutics, Inc.: Helix Holdings Ii LLC (22.6%, Schedule 13D/A, filed 2025-08-13), Bihua Chen (22.32%, Schedule 13D/A, filed 2026-07-06), Bridgebio Pharma LLC (17.5%, Schedule 13D, filed 2025-08-18), Deerfield Management Company, L.P. (6.17%, Schedule 13G, filed 2025-08-18) and Bc Global Opportunities Ix LP (5.5%, Schedule 13G, filed 2025-09-03); 1 more is listed above.
Who are the largest shareholders of BridgeBio Oncology Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of BridgeBio Oncology Therapeutics, Inc. on this page are Helix Holdings Ii LLC (22.6%), Bihua Chen (22.32%) and Bridgebio Pharma LLC (17.5%).
When did Helix Holdings Ii LLC buy into BridgeBio Oncology Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Helix Holdings Ii LLC on this page is the Schedule 13D/A, filed 2025-08-13, reporting 22.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BridgeBio Oncology Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BridgeBio Oncology Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BridgeBio Oncology Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-22 | Michelle Doig | Director | departed | 2026-06-16 |
| Form 8-K, 2026-04-23 | Eli Wallace | Director | departed |
Which insiders own BridgeBio Oncology Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 17,878,594 shares (22.3% of shares outstanding), held indirectly through Via Master Fund and 2 others (Form 4, 2026-07-06).
- BridgeBio Pharma LLC, a 10% owner: 14,589,846 shares (18.2% of shares outstanding), on a joint filing (Form 4, 2025-10-16).
- , Inc., a 10% owner: 14,589,846 shares (18.2% of shares outstanding), on a joint filing (Form 4, 2025-10-16).
- , the chief med and amp: 43,529 shares (0.05% of shares outstanding) (Form 4, 2026-10-05).
- , the chief executive and president: 43,529 shares (0.05% of shares outstanding) (Form 4, 2026-10-05).
Shares outstanding: 80,174,267 as of 2026-08-06, from the company's latest SEC cover page.
How much has BridgeBio Oncology Therapeutics, Inc. raised?
Latest IPO step: BridgeBio Oncology Therapeutics, Inc. filed to go public (S-1, 2025-08-29).
IPO filings: S-1, 2025-08-29, 424B4, 2025-07-10; ticker BBOT on Nasdaq Global Market.
Keep reading
More on BridgeBio Oncology Therapeutics, Inc. and the records around it.
BridgeBio Oncology Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes Jun 2026
Companies that share a holder
- Bihua Chen also filed stake reports on 1 other company: MoonLake Immunotherapeutics (Oct 2025)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Sculptor Capital LP also filed stake reports on 40 other companies: Helix Acquisition Corp. III (Oct 2026), Live Oak Acquisition Corp. VI (Oct 2026), Amanat Acquisition Corp (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bridgebio-oncology-therapeutics